New Psychoactive Substances (NPS)

New Psychoactive Substances (NPS): synthetic cannabinoids HHC, THCP, H4CBD — health risks and regulatory framework in France.

The New Psychoactive Substances (NPS, or 'designer drugs') are a generic category covering hundreds of synthetic molecules designed to mimic the effects of existing psychoactive substances — while circumventing existing prohibitions.

In the hemp / CBD sector, NPS include semi-synthetic or fully synthetic cannabinoids: HHC, HHC-O, THCP, THCO, H4CBD, CBDP , etc. They are at the center of major regulatory and health debates in 2025-2026 in France and Europe.

Nature of synthetic cannabinoids

Most CBD-derived NPS:

1. Start from natural CBD extracted from legal hemp (< 0.3% THC) 2. Apply a chemical transformation in laboratory (hydrogenation, esterification, isomerization, fluorination…) 3. Obtain a structurally different molecule that often has psychoactive effects close to or stronger than THC

Examples:

Molecule Process Reported effect --- --- --- HHC (Hexahydrocannabinol) hydrogenation of THC similar to THC, 70% intensity HHC-O esterification of HHC stronger, longer THCP (Tetrahydrocannabiphorol) natural / synthetic up to 33× more affinity for CB1 H4CBD hydrogenation of CBD sedative, not very psychoactive CBDP natural / synthetic poorly studied

Health risks

NPS pose multiple health concerns:

- Lack of medium-term human data (years to decades) — long-term effects unknown - Variability of laboratory preparations — synthesis residues, undeclared isomers - Unpredictable interactions with the endocannabinoid system - Risks for cardiovascular and mental health documented in clinical reports - Adulterated products : NPS sometimes presented as 'CBD' to consumers who didn't choose them

The OFDT (French Observatory on Drugs and Toxic Tendencies) and the EMCDDA (European Drug Agency) document hundreds of NPS cases per year.

Legal status in France

France follows a case-by-case policy: each new NPS is individually classified by MILDECA (interministerial mission to combat drugs) and added to the list of narcotics.

State in May 2026:

- HHC, HHCPO, HHCP, THCP : classified as narcotic by the order of 12 June 2023 - H4CBD : not yet classified as narcotic but under surveillance by ANSM - Other NPS : assessed case-by-case

Products containing classified NPS are therefore illegal in France — sale, production, possession are punishable offenses.

NPS vs natural artisanal CBD

The artisanal French hemp industry strongly defends the distinction between:

- Natural artisanal CBD : extracted from low-THC cultivars (≤ 0.3%), traceable, lab-analyzed, no chemical transformation - NPS : laboratory transformations producing molecules absent from the natural plant

L'Herbe en France and the AFPC (French Federation of Cannabinoid Producers) refuse the marketing of NPS on their platforms, in order to defend the artisanal industry framework and consumer health.

Why this matters for English speakers

The European NPS phenomenon is growing rapidly — and CBD products sold across borders in 2024-2026 sometimes contain undeclared NPS. Importers, journalists and researchers studying the European hemp market should:

- Demand lot-specific certificates of analysis mentioning synthetic cannabinoids - Distinguish artisanal natural CBD from semi-synthetic 'wellness' products that flood gas stations and convenience stores in some EU member states - Follow MILDECA classifications and EMCDDA reports for the latest legal status

- CBD in France — Legal framework - Cannabidiol (CBD) - Cannabinol (CBN) - Hemp glossary